Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

News SummaryMost relevantAll newsSector news 

Catalyst Pharmaceutical Partners, Inc. : Catalyst Receives Guidance From NASDAQ Regarding Minimum Bid Price Requirement

share with twitter share with LinkedIn share with facebook
share via e-mail
12/27/2012 | 03:05pm CET

CORAL GABLES, Fla., Dec. 27, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it received a Nasdaq Staff Deficiency Letter, dated December 24, 2012, indicating that the Company is not in compliance with the Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

The Nasdaq Listing Rules (the "Rules") require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets this requirement. In light of the deficiency, the Rules also provide the Company with a grace period of 180 calendar days in which to regain compliance. If at any time during this grace period the bid price of the Company's security closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Stock Market will provide the Company with a written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance with the Rule prior to the expiration of the grace period, the Company may be eligible for an additional 180-day grace period if at such time it meets the initial listing standards for listing on the Nasdaq Capital Market, with the exception of the bid price requirement.

The Company understands the Nasdaq requirements and believes it will be able to regain compliance with the Rules within the allotted grace period.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting orphan drug diseases and disorders of the central nervous system. Catalyst has three products in development, Firdapse™, which Catalyst plans to develop for commercialization in North America as a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), CPP-115, a GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin, which Catalyst plans to develop for the treatment of epilepsy (primarily infantile spasms) and CPP-109 (vigabatrin), which Catalyst hopes to develop for the treatment of Tourette's Disorder. For additional information about Catalyst, please visit www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the Company will be able to regain compliance with the Rules within any applicable grace periods, whether any of the Company's product candidates will ever be approved for commercialization, and those factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany

         Catalyst Pharmaceutical Partners

         Chief Executive Officer

         (305) 529-2522


         Melody Carey

         Rx Communications Group


         (917) 322-2571

Source: Catalyst Pharmaceutical Partners, Inc.

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
12/08 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
12/08 Catalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients w..
11/21 CATALYST PHARMACEUTICALS : to Participate in the 28th Annual Piper Jaffray Healt..
11/10 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Announces Third Quarte..
11/09 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
11/09 Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and P..
11/01 Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference C..
10/31 CATALYST PHARMACEUTICALS, INC. (CPRX : FDA OKs Phase 3 Firdapse Study; Shares Hi..
10/31 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Receives Special Proto..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/10 Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q3 2016 Resul..
11/09 Catalyst Pharmaceutical beats by $0.01
10/31 FDA signs off on design of Catalyst Pharma's late-stage study of Firdapse in ..
10/07 Healthcare ratings roundup - Upgrades/Downgrades
10/05 Catalyst Pharma shows some oomph; shares up 29%
Financials ($)
Sales 2016 -
EBIT 2016 -20,6 M
Net income 2016 -19,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 0
Capi. / Sales 2017 0
Capitalization 97,8 M
More Financials
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Full-screen chart
Technical analysis trends CATALYST PHARMACE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 4,38 $
Spread / Average Target 271%
Consensus details
EPS Revisions
More Estimates Revisions
Patrick J. McEnany Chairman, President, CEO & Contact Person
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer
Philip H. Coelho Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-11.63%106 716
GILEAD SCIENCES, INC.-28.16%95 779
ACTELION LTD50.21%22 204
More Results